The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Open accessAbstract
BACKGROUND: Clostridium difficile infection is a serious diarrheal illness associated with substantial morbidity and mortality. Patients generally have a response to oral vancomycin or metronidazole; however, the rate of recurrence is high. This phase 3 clinical trial compared the efficacy and safety of fidaxomicin with those of vancomycin in treating C. difficile infection. METHODS: Adults with acute symptoms of C. difficile infection and a positive result on a stool toxin test were eligible for study entry. We randomly assigned patients to receive fidaxomicin (200 mg twice daily) or vancomycin (125 mg four times daily) orally for 10 days. The primary end point was clinical cure (resolution of symptoms and no need for further therapy for C. difficile infection as of the second day after the end of the course of therapy). The secondary end points were recurrence of C. difficile infection (diarrhea and a positive result on a stool toxin test within 4 weeks after treatment) and global cure (i.e., cure with no recurrence). RESULTS: A total of 629 patients were enrolled, of whom 548 (87.1%) could be evaluated for the per-protocol analysis. The rates of clinical cure with fidaxomicin were noninferior to those with vancomycin in both the modified intention-to-treat analysis (88.2% with fidaxomicin and 85.8% with vancomycin) and the per-protocol analysis (92.1% and 89.8%, respectively). Significantly fewer patients in the fidaxomicin group than in the vancomycin group had a recurrence of the infection, in both the modified intention-to-treat analysis (15.4% vs. 25.3%, P=0.005) and the per-protocol analysis (13.3% vs. 24.0%, P=0.004). The lower rate of recurrence was seen in patients with non–North American Pulsed Field type 1 strains. The adverse-event profile was similar for the two therapies. CONCLUSIONS: The rates of clinical cure after treatment with fidaxomicin were noninferior to those after treatment with vancomycin. Fidaxomicin was associated with a significantly lower rate of recurrence of C. difficile infection associated with non–North American Pulsed Field type 1 strains. (Funded by Optimer Pharmaceuticals; ClinicalTrials.gov number, NCT00314951.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Self-citationClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031
McDonald, L. C., Owings, M., & Jernigan, D. B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1203.051064 · Cited by 788
Clostridium Difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/648363 · Cited by 631
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C. (2005) · Clinical Infectious Diseases · doi:10.1086/430315 · Cited by 570
Relatively Poor Outcome after Treatment of Clostridium difficile Colitis with Metronidazole
Musher, D. M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., & Hamill, R. J. (2005) · Clinical Infectious Diseases · doi:10.1086/430311 · Cited by 504
Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F., & Mascola, L. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1309.061116 · Cited by 429
Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Nelson, R. L., Suda, K. J., & Evans, C. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub5 · Cited by 366
Cited by
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Clostridium difficile Infection
Leffler, D. A., & Lamont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,450
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Gough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
Discovery of microbial natural products by activation of silent biosynthetic gene clusters
Rutledge, P. J., & Challis, G. L. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3496 · Cited by 986
Clostridium difficile infection
Smits, W. K., Lyras, D., Lacy, D. B., Wilcox, M. H., & Kuijper, E. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.20 · Cited by 853
Cornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., Sears, P., & Gorbach, S. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70374-7 · Cited by 761
Self-citationHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738
Clostridium difficile infection: review
Czepiel, J., Dróżdż, M., Pituch, H., Kuijper, E. J., Perucki, W., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A., & Biesiada, G. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03539-6 · Cited by 702
Fecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677
Johnson, S., Lavergne, V., Skinner, A. M., Gonzales-Luna, A. J., Garey, K. W., Kelly, C. P., & Wilcox, M. H. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab549 · Cited by 674
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672
Kelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
Natural Products as Platforms To Overcome Antibiotic Resistance
Rossiter, S. E., Fletcher, M. H., & Wuest, W. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00283 · Cited by 622
Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., Chang, H.-J., Coward, S., Goodman, K. J., Xu, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.17077 · Cited by 615
Self-citationACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Kelly, C. R., Fischer, M., Allegretti, J. R., LaPlante, K., Stewart, D. B., Limketkai, B. N., & Stollman, N. H. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001278 · Cited by 579
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
Burden of Clostridium difficile on the Healthcare System
Dubberke, E. R., & Olsen, M. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis335 · Cited by 557
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2106516 · Cited by 558
Self-citationLawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002995 · Cited by 540
Johnson, S., Louie, T. J., Gerding, D. N., Cornely, O. A., Chasan-Taber, S., Fitts, D., Gelone, S. P., Broom, C., Davidson, D. M., & for the Polymer Alternative for CDI Treatment (PACT) investigators (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu313 · Cited by 527
Self-citationTheriot, C. M., Bowman, A. A., & Young, V. B. (2016) · mSphere · doi:10.1128/msphere.00045-15 · Cited by 481
Fecal microbiota transplantation: in perspective
Gupta, S., Allen-Vercoe, E., & Petrof, E. O. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15607414 · Cited by 481
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu135 · Cited by 467
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundDiagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Weingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., Sadowsky, M. J., & Khoruts, A. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2013 · Cited by 423
Carey-Ann, B. D., & Carroll, K. C. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-13 · Cited by 423
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
Cornely, O. A., Miller, M. A., Louie, T. J., Crook, D. W., & Gorbach, S. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis462 · Cited by 401
Self-citationCan we identify patients at high risk of recurrent Clostridium difficile infection?
Kelly, C. P. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12046 · Cited by 396
Hvas, C. L., Dahl Jørgensen, S. M., Jørgensen, S. P., Storgaard, M., Lemming, L., Hansen, M. M., Erikstrup, C., & Dahlerup, J. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.019 · Cited by 390
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371
Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I., & Wilt, T. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2693 · Cited by 371
Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Nelson, R. L., Suda, K. J., & Evans, C. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub5 · Cited by 366
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Neal, M. D., Alverdy, J. C., Hall, D. E., Simmons, R. L., & Zuckerbraun, B. S. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31822ade48 · Cited by 341
Arasaradnam, R. P., Brown, S., Forbes, A., Fox, M. R., Hungin, P., Kelman, L., Major, G., O’Connor, M., Sanders, D. S., Sinha, R., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315909 · Cited by 332
Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., Moore, D. J., Colville, A., Bhala, N., Iqbal, T. H., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-316818 · Cited by 332
Abou Chakra, C. N., Pepin, J., Sirard, S., & Valiquette, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098400 · Cited by 328
“Several novel treatments of CDI are being studied, some of which have been associated with a lower risk of recurrence [9–11].”
BackgroundDingle, K. E., Didelot, X., Quan, T. P., Eyre, D. W., Stoesser, N., Golubchik, T., Harding, R. M., Wilson, D. J., Griffiths, D., Vaughan, A., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30514-x · Cited by 328
Self-citationLouie, T. J., Cannon, K., Byrne, B., Emery, J., Ward, L., Eyben, M., & Krulicki, W. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis338 · Cited by 310
Self-citationDiversity and Evolution in the Genome of Clostridium difficile
Knight, D. R., Elliott, B., Chang, B. J., Perkins, T. T., & Riley, T. V. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00127-14 · Cited by 286
Clostridium difficile Infection: A Worldwide Disease
Burke, K. E., & Lamont, J. T. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.1.1 · Cited by 274
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Biodiversity and functional genomics in the human microbiome
Morgan, X. C., Segata, N., & Huttenhower, C. (2013) · Trends in Genetics · doi:10.1016/j.tig.2012.09.005 · Cited by 263
Crook, D. W., Walker, A. S., Kean, Y., Weiss, K., Cornely, O. A., Miller, M. A., Esposito, R., Louie, T. J., Stoesser, N. E., Young, B. C., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis499 · Cited by 260
Self-citationRecent advances in the understanding of antibiotic resistance in Clostridium difficile infection
Spigaglia, P. (2016) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936115622891 · Cited by 254
McDonald, E. G., Milligan, J., Frenette, C., & Lee, T. C. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.42 · Cited by 216
Lewis, B. B., Buffie, C. G., Carter, R. A., Leiner, I., Toussaint, N. C., Miller, L. C., Gobourne, A., Ling, L., & Pamer, E. G. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv256 · Cited by 197
Shahinas, D., Silverman, M., Sittler, T., Chiu, C., Kim, P., Allen-Vercoe, E., Weese, S., Wong, A., Low, D. E., & Pillai, D. R. (2012) · mBio · doi:10.1128/mbio.00338-12 · Cited by 191
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
Lo Vecchio, A., & Zacur, G. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834bc9a9 · Cited by 183
Clostridium difficile – From Colonization to Infection
Schäffler, H., & Breitrück, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00646 · Cited by 174
Regulation, risk and safety of Faecal Microbiota Transplant
Merrick, B., Allen, L., Masirah M Zain, N., Forbes, B., Shawcross, D. L., & Goldenberg, S. D. (2020) · Infection Prevention in Practice · doi:10.1016/j.infpip.2020.100069 · Cited by 171
“fidaxomicin [67,68] and bezlotoxumab [69,70]) are established, have well described pharmacodynamics, pharmacokinetics and long term safety data, attempting FMT without making use of these would be a retrograde approach.”
Sartelli, M., Di Bella, S., McFarland, L. V., Khanna, S., Furuya-Kanamori, L., Abuzeid, N., Abu-Zidan, F. M., Ansaloni, L., Augustin, G., Bala, M., et al. (2019) · World Journal of Emergency Surgery · doi:10.1186/s13017-019-0228-3 · Cited by 159
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Models for the study of Clostridium difficile infection
Best, E. L., Freeman, J., & Wilcox, M. H. (2012) · Gut Microbes · doi:10.4161/gmic.19526 · Cited by 135
Gebhart, D., Lok, S., Clare, S., Tomas, M., Stares, M., Scholl, D., Donskey, C. J., Lawley, T. D., & Govoni, G. R. (2015) · mBio · doi:10.1128/mbio.02368-14 · Cited by 127
Neemann, K., Eichele, D. D., Smith, P. W., Bociek, R., Akhtari, M., & Freifeld, A. (2012) · Transplant Infectious Disease · doi:10.1111/tid.12017 · Cited by 107
“Numerous alternative pharmacologic therapies have been described for recurrent or fulminant disease, although none has proven superior to oral vancomycin (4, 11, 34).”
BackgroundSims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55758 · Cited by 83
Self-citationVarier, R. U., Biltaji, E., Smith, K. J., Roberts, M. S., Kyle Jensen, M., LaFleur, J., & Nelson, R. E. (2015) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2014.80 · Cited by 68
Trubiano, J. A., Gardiner, B., Kwong, J. C., Ward, P., Testro, A. G., & Charles, P. G. P. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835b2da9 · Cited by 64
Bakken, J. S., Polgreen, P. M., Beekmann, S. E., Riedo, F. X., & Streit, J. A. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.08.007 · Cited by 63
Yun, B., Song, M., Park, D.-J., & Oh, S. (2017) · Korean Journal for Food Science of Animal Resources · doi:10.5851/kosfa.2017.37.3.368 · Cited by 35
Clostridium difficile in the Long-Term Care Facility: Prevention and Management
Jump, R. L. P., & Donskey, C. J. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-014-0108-3 · Cited by 35
Aby, E. S., Vaughn, B. P., Enns, E. A., & Rajasingham, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac207 · Cited by 28
Metadata
- Authors
- Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-02-03
- Volume
- 364
- Issue
- 5
- Pages
- 422-431
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113556993
- Cited by
- 1,585
- References
- 34
- FWCI
- 96.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.